Taken together, these findings suggest that incretin related agents, including GLP-1 analogues, are useful therapeutic tools for type 2 diabetes mellitus and may ameliorate the risk of bone fracture in these patients. The gene discussed is GCG; the disease is type 2 diabetes mellitus.